Clinical trials
Relapsed Adult AML clinical trials
Below are recruiting relapsed adult aml clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
Phoenix, ArizonaAges 4 weeks–21 years - NCT06177067RecruitingPhase 1
Study of 3 drugs for young AML patients with genetic changes
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
San Diego, CaliforniaAges 1–30 - NCT05190471RecruitingPhase 1
Study drug for adults with AML that did not respond or returned
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
La Jolla, CaliforniaAges 18 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Duarte, CaliforniaAges 18 years+ - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Tampa, FloridaAges 18–80 - NCT05772559Recruiting
Study of AML genes and drug response in young patients
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
AmiensAges Up to 25 years - NCT05884333RecruitingPhase 2
Cord blood transplant for adults with blood cancer
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
New York, New YorkAges 21–65 - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT04644016RecruitingPhase 2
Cord blood transplant for children and young adults with blood cancers
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
New York, New YorkAges Up to 21 years - NCT06642025RecruitingEarly Phase 1
EX02 car-t cells for hard-to-treat acute myeloid leukemia
This trial tests a new treatment called EX02 CAR-T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses your own immune cells, modified to target a specific marker on leukemia cells, to help fight the cancer.
Hefei, AnhuiAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06994676RecruitingPhase 1
Study of CBX-250 for advanced myeloid leukemias
This study tests an experimental drug, CBX-250, for people with certain advanced blood cancers (like AML) that have not responded to standard treatments or have returned. The drug works only for people who have a specific genetic marker (HLA-A*02:01). The goal is to see if it is safe and how well it works.
Duarte, CaliforniaAges 12 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Phoenix, ArizonaAges 18 years+
Hear when a new Relapsed Adult AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed adult aml?
- Yes. Clin2 currently lists 42 recruiting relapsed adult aml studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed adult aml trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed adult aml trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.